Some experts say we’re in “the golden age of biotechnology.” Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past. This golden age is also presenting tremendous opportunities for investors.
Biotech stocks offer the potential for substantial long-term returns. The best biotech stocks to buy right now boast robust pipelines, and some already have winning drugs on the market. Our pick for the day ticks all of these boxes.
Vertex Pharmaceuticals (VRTX) is the undisputed leader in cystic fibrosis therapies. The company’s portfolio of approved CF drugs will deliver at least an estimated $8.4 billion this year, made possible by intense market penetration and decades-long devotion to research and development in the space.
So far, the company has managed to remain strongly profitable and has continued to expand revenue within the CF market at a steady pace. If management’s plans for expanded approvals for younger cohorts continue to come to fruition over the next few years, Vertex will eventually treat as many as 90% of all people with CF.
The company is moving its pipeline beyond CF with a handful of mid-stage clinical programs for pain relief, kidney disease, and hematologic genetic disorders like sickle cell disease. In other words, even if it eventually corners the entire CF therapies market, there will still be other growth opportunities.
[stock_market_widget type=”accordion” template=”extended” color=”#5679FF” assets=”VRTX” start_expanded=”true” display_currency_symbol=”true” api=”yf”]
